Showing 261 - 280 results of 56,668 for search '(( 05 a decrease ) OR ( 50 ((((we decrease) OR (nn decrease))) OR (mean decrease)) ))', query time: 0.57s Refine Results
  1. 261
  2. 262
  3. 263
  4. 264
  5. 265
  6. 266
  7. 267
  8. 268
  9. 269
  10. 270
  11. 271

    Decrease in apoptosis in the ischemic myocardium. by Laura A. Scrimgeour (9367459)

    Published 2020
    “…<p>There is an increase seen in JNK, pBAD, and pBAD/BAD with a decrease in pBCL-2, pBCL-2/BCL-2, and Caspase 3. …”
  12. 272
  13. 273
  14. 274
  15. 275

    DataSheet_1_IL-40: A New B Cell-Associated Cytokine Up-Regulated in Rheumatoid Arthritis Decreases Following the Rituximab Therapy and Correlates With Disease Activity, Autoantibod... by Adela Navrátilová (11589532)

    Published 2021
    “…As B cells play a pivotal role in autoimmunity, we investigated the function of IL-40 in rheumatoid arthritis (RA).…”
  16. 276

    Table_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

    Published 2022
    “…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”
  17. 277

    Image_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

    Published 2022
    “…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”
  18. 278
  19. 279
  20. 280

    Comparison of MAP@0.5 results from experiments. by Junyan Wang (4738518)

    Published 2025
    “…Experimental results demonstrate that SCI-YOLO11 achieves a 3.2% improvement over baseline models in terms of MAP@0.5 metric; precision and recall rates increase by 2.6% and 3.7%, respectively. …”